cMyBPC Biomarker Panels for Early Type 1/Type 2 MI Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to reliably differentiate between Type 1 and Type 2 myocardial infarctions, which have distinct treatment requirements, due to insufficient discriminatory power of existing biomarkers like troponins and cMyBPC, leading to potential unfavorable outcomes when default treatments for Type 1 are applied to Type 2.
Innovation Solution
A combination of the cardiac biomarker cMyBPC with additional biomarkers such as BMP10-type peptide, FGF23, BNP-type peptide, GDF-15, ANG2, CRP, or lipids like Cholesterol or LDL is used to improve differentiation between Type 1 and Type 2 myocardial infarctions through logistic regression analysis, enhancing the area under the receiver operating characteristic (AUC) for accurate assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biomarkers like troponins and cMyBPC are used for diagnosis, then the diagnostic process is simple and quick, but the discriminatory power between Type 1 and Type 2 myocardial infarction is insufficient
Solution Approach 1:
The patent combines multiple biomarkers (cMyBPC, BMP10, FGF23, BNP, GDF-15, ANG2, CRP, ESM1, and lipid biomarkers) into a composite diagnostic panel to achieve superior discriminatory power between Type 1 and Type 2 myocardial infarction. This merging of multiple detection targets resolves the contradiction by trading increased assay complexity for significantly improved diagnostic accuracy.
Solution Approach 2:
The diagnostic approach uses a composite biomarker profile rather than a single marker, integrating information from multiple biological pathways (cardiac injury, stress response, inflammation, and metabolic markers) to create a more nuanced diagnostic picture that accurately distinguishes between infarction types.
2Reliability
If a single biomarker assay is used, then the testing process is fast and cost-effective, but the ability to differentiate between infarction types is limited
Solution Approach 1:
The patent implements a tiered diagnostic approach where a panel of biomarkers is measured simultaneously from a single blood sample, allowing for comprehensive assessment without sequential testing. This preliminary action of measuring multiple markers at once resolves the contradiction by eliminating the time loss of sequential testing while maintaining high diagnostic reliability.
3Productivity
If default treatment for Type 1 myocardial infarction is applied to Type 2 cases, then treatment can be initiated immediately, but unfavorable outcomes may occur
Solution Approach 1:
The patent uses biomarker profile feedback to guide treatment decisions, where the pattern of elevated markers provides real-time information about the underlying pathophysiology. This feedback mechanism allows clinicians to differentiate between Type 1 and Type 2 infarction quickly and initiate appropriate treatment, resolving the contradiction between speed and appropriateness by making treatment decisions based on immediate diagnostic information.
Data Source
AI summary
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.